Adjuvant gimeracil/oteracil/tegafur administered for 4 weeks then 2 weeks rest versus administration for 2 weeks then 1 week rest in patients with gastric cancer

Trial Profile

Adjuvant gimeracil/oteracil/tegafur administered for 4 weeks then 2 weeks rest versus administration for 2 weeks then 1 week rest in patients with gastric cancer

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Oct 2012

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary)
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Oct 2012 New trial record
    • 02 Oct 2012 Interim results presented at the 37th Congress of the European Society for Medical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top